CHLAMYDIA PNEUMONIAE, a gram-negative obligate respiratory pathogen, has been suggested to be a possible trigger or even causative agent in the pathogenesis of atherosclerosis. This hypothesis was first presented by Finnish investigators,
1,2 who showed that patients with coronary heart disease (CHD) had elevated IgG and IgA titers of antibodies and specific circulating immune complexes to
Chlamydia. This result has been replicated in other populations,
3-5 and, moreover, the presence of
Chlamydia particles in atherosclerotic lesions in coronary and carotid arteries, the aorta, and abdominal aortic aneurysms has been directly demonstrated using polymerase chain reaction and immunohistochemical methods.
6-9 These findings have led to eradication trials with antibiotics. In the rabbit model,
Chlamydia infection accelerates the development of atherosclerosis, and treatment with azithromycin prevents it.
10 Also, in human studies, azithromycin treatment may reduce the risk of cardiac events in patients with unstable angina or non–Q wave myocardial infarction (MI)
11 or in male survivors of MI.
12